Literature DB >> 22826563

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Valeria Visconte1, Heesun J Rogers, Jarnail Singh, John Barnard, Manoj Bupathi, Fabiola Traina, James McMahon, Hideki Makishima, Hadrian Szpurka, Anna Jankowska, Andres Jerez, Mikkael A Sekeres, Yogen Saunthararajah, Anjali S Advani, Edward Copelan, Haruhiko Koseki, Kyoichi Isono, Richard A Padgett, Sami Osman, Kazunori Koide, Christine O'Keefe, Jaroslaw P Maciejewski, Ramon V Tiu.   

Abstract

Whole exome/genome sequencing has been fundamental in the identification of somatic mutations in the spliceosome machinery in myelodysplastic syndromes (MDSs) and other hematologic disorders. SF3B1, splicing factor 3b subunit 1 is mutated in 60%-80% of refractory anemia with ring sideroblasts (RARS) and RARS associated with thrombocytosis (RARS-T), 2 distinct subtypes of MDS and MDS/myeloproliferative neoplasms (MDSs/MPNs). An idiosyncratic feature of RARS/RARS-T is the presence of abnormal sideroblasts characterized by iron overload in the mitochondria, called RS. Based on the high frequency of mutations of SF3B1 in RARS/RARS-T, we investigated the consequences of SF3B1 alterations. Ultrastructurally, SF3B1 mutants showed altered iron distribution characterized by coarse iron deposits compared with wild-type RARS patients by transmission electron microscopy. SF3B1 knockdown experiments in K562 cells resulted in down-regulation of U2-type intron-splicing by RT-PCR. RNA-sequencing analysis of SF3B1 mutants showed differentially used genes relevant in MDS pathogenesis, such as ASXL1, CBL, EZH, and RUNX families. A SF3B pharmacologic inhibitor, meayamycin, induced the formation of RS in healthy BM cells. Further, BM aspirates of Sf3b1 heterozygous knockout mice showed RS by Prussian blue. In conclusion, we report the first experimental evidence of the association between SF3B1 and RS phenotype. Our data suggest that SF3B1 haploinsufficiency leads to RS formation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22826563      PMCID: PMC3476536          DOI: 10.1182/blood-2012-05-430876

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  A novel U2 and U11/U12 snRNP protein that associates with the pre-mRNA branch site.

Authors:  C L Will; C Schneider; A M MacMillan; N F Katopodis; G Neubauer; M Wilm; R Lührmann; C C Query
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

2.  SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications.

Authors:  F Damm; F Thol; O Kosmider; S Kade; P Löffeld; F Dreyfus; A Stamatoullas-Bastard; A Tanguy-Schmidt; O Beyne-Rauzy; S de Botton; A Guerci-Bresler; G Göhring; B Schlegelberger; A Ganser; O A Bernard; M Fontenay; M Heuser
Journal:  Leukemia       Date:  2011-11-08       Impact factor: 11.528

3.  Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1.

Authors:  Kyoichi Isono; Yoko Mizutani-Koseki; Toshihisa Komori; Marion S Schmidt-Zachmann; Haruhiko Koseki
Journal:  Genes Dev       Date:  2005-03-01       Impact factor: 11.361

4.  Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.

Authors:  Daisuke Kaida; Hajime Motoyoshi; Etsu Tashiro; Takayuki Nojima; Masatoshi Hagiwara; Ken Ishigami; Hidenori Watanabe; Takeshi Kitahara; Tatsuhiko Yoshida; Hidenori Nakajima; Tokio Tani; Sueharu Horinouchi; Minoru Yoshida
Journal:  Nat Chem Biol       Date:  2007-07-22       Impact factor: 15.040

5.  Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue.

Authors:  Brian J Albert; Ananthapadmanabhan Sivaramakrishnan; Tadaatsu Naka; Nancy L Czaicki; Kazunori Koide
Journal:  J Am Chem Soc       Date:  2007-02-06       Impact factor: 15.419

Review 6.  Myelodysplastic syndromes.

Authors:  Peter L Greenberg; Neal S Young; Norbert Gattermann
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2002

7.  Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

Authors:  Andrea Pellagatti; Mario Cazzola; Aristoteles A N Giagounidis; Luca Malcovati; Matteo G Della Porta; Sally Killick; Lisa J Campbell; Li Wang; Cordelia F Langford; Carrie Fidler; David Oscier; Carlo Aul; James S Wainscoat; Jacqueline Boultwood
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113

8.  Energy-dispersive X-ray analysis of the mitochondria of sideroblastic anaemia.

Authors:  J A Grasso; T J Myers; J D Hines; A L Sullivan
Journal:  Br J Haematol       Date:  1980-09       Impact factor: 6.998

9.  The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site.

Authors:  Katrin de Graaf; Hanna Czajkowska; Sabine Rottmann; Len C Packman; Richard Lilischkis; Bernhard Lüscher; Walter Becker
Journal:  BMC Biochem       Date:  2006-03-02       Impact factor: 4.059

10.  The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.

Authors:  Jacqueline Boultwood; Andrea Pellagatti; Maryam Nikpour; Beena Pushkaran; Carrie Fidler; Helen Cattan; Tim J Littlewood; Luca Malcovati; Matteo G Della Porta; Martin Jädersten; Sally Killick; Aristoteles Giagounidis; David Bowen; Eva Hellström-Lindberg; Mario Cazzola; James S Wainscoat
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

View more
  78 in total

1.  SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.

Authors:  Teresa Mortera-Blanco; Marios Dimitriou; Petter S Woll; Mohsen Karimi; Edda Elvarsdottir; Simona Conte; Magnus Tobiasson; Monika Jansson; Iyadh Douagi; Matahi Moarii; Leonie Saft; Elli Papaemmanuil; Sten Eirik W Jacobsen; Eva Hellström-Lindberg
Journal:  Blood       Date:  2017-06-20       Impact factor: 22.113

2.  SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype.

Authors:  Valeria Visconte; Ali Tabarroki; Heesun J Rogers; Edy Hasrouni; Fabiola Traina; Hideki Makishima; Betty K Hamilton; Yang Liu; Christine O'Keefe; Alan Lichtin; Leonard Horwitz; Mikkael A Sekeres; Fred H Hsieh; Ramon V Tiu
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

3.  Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.

Authors:  Marshall A Lichtman
Journal:  Oncologist       Date:  2013-08-27

4.  Linezolid induces ring sideroblasts.

Authors:  Christophe Willekens; Florent Dumezy; Thomas Boyer; Aline Renneville; Julien Rossignol; Céline Berthon; Angélique Cotteau-Leroy; Lotfi Mehiaoui; Bruno Quesnel; Claude Preudhomme
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

Review 5.  [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].

Authors:  A H Schmitt-Graeff; M J Müller; P Fisch
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

6.  Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Authors:  F Traina; V Visconte; P Elson; A Tabarroki; A M Jankowska; E Hasrouni; Y Sugimoto; H Szpurka; H Makishima; C L O'Keefe; M A Sekeres; A S Advani; M Kalaycio; E A Copelan; Y Saunthararajah; S T Olalla Saad; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

7.  Modeling SF3B1 Mutations in Cancer: Advances, Challenges, and Opportunities.

Authors:  Daichi Inoue; Omar Abdel-Wahab
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

8.  Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

Authors:  Esther A Obeng; Ryan J Chappell; Michael Seiler; Michelle C Chen; Dean R Campagna; Paul J Schmidt; Rebekka K Schneider; Allegra M Lord; Lili Wang; Rutendo G Gambe; Marie E McConkey; Abdullah M Ali; Azra Raza; Lihua Yu; Silvia Buonamici; Peter G Smith; Ann Mullally; Catherine J Wu; Mark D Fleming; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

Review 9.  Splicing factor gene mutations in hematologic malignancies.

Authors:  Borja Saez; Matthew J Walter; Timothy A Graubert
Journal:  Blood       Date:  2016-12-09       Impact factor: 22.113

10.  Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Authors:  Véronique Gelsi-Boyer; Nathalie Cervera; François Bertucci; Mandy Brecqueville; Pascal Finetti; Anne Murati; Christine Arnoulet; Marie-Joelle Mozziconacci; Ken I Mills; Nicholas C P Cross; Norbert Vey; Daniel Birnbaum
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.